# ğŸ¨ UI Mockups: Research Question Hierarchy & New Features

**Date**: November 17, 2025  
**Purpose**: Detailed UI/UX designs for pivoted product

---

## ğŸ“± Part 1: Research Question Tab (Redesigned)

### Current State (Before)

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ¯ Research Question                                            â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                 â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”â”‚
â”‚ â”‚ [Text Area - Single Field]                                  â”‚â”‚
â”‚ â”‚                                                             â”‚â”‚
â”‚ â”‚ "Investigating the role of CRISPR in cancer therapy..."    â”‚â”‚
â”‚ â”‚                                                             â”‚â”‚
â”‚ â”‚                                                             â”‚â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜â”‚
â”‚                                                                 â”‚
â”‚ [Save Button]                                                   â”‚
â”‚                                                                 â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”â”‚
â”‚ â”‚ Quick Stats                                                 â”‚â”‚
â”‚ â”‚ ğŸ“„ Papers: 45  ğŸ“š Collections: 3  ğŸ“ Notes: 12             â”‚â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

**Problems:**
- âŒ Just a text field (no structure)
- âŒ No sub-questions
- âŒ No evidence linking
- âŒ No hypothesis tracking
- âŒ Papers float in collections (not linked to questions)

---

### New State (After)

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ¯ Research Questions & Hypotheses                                              â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                                 â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”â”‚
â”‚ â”‚ ğŸ¯ Main Research Question                                                   â”‚â”‚
â”‚ â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”â”‚â”‚
â”‚ â”‚ â”‚ What are the mechanisms by which CRISPR-Cas9 enhances cancer therapy?  â”‚â”‚â”‚
â”‚ â”‚ â”‚                                                                         â”‚â”‚â”‚
â”‚ â”‚ â”‚ Status: ğŸŸ¢ Exploring  â”‚  Priority: ğŸ”´ High  â”‚  Evidence: 23 papers    â”‚â”‚â”‚
â”‚ â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜â”‚â”‚
â”‚ â”‚                                                                             â”‚â”‚
â”‚ â”‚ [+ Add Sub-Question]  [ğŸ”— Link Papers]  [ğŸ’¡ Generate Hypotheses]          â”‚â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜â”‚
â”‚                                                                                 â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”â”‚
â”‚ â”‚ ğŸ“Š Question Hierarchy (Tree View)                                           â”‚â”‚
â”‚ â”‚                                                                             â”‚â”‚
â”‚ â”‚ â–¼ ğŸ¯ Main Question: CRISPR mechanisms in cancer therapy                    â”‚â”‚
â”‚ â”‚   â”‚                                                                         â”‚â”‚
â”‚ â”‚   â”œâ”€â–¼ ğŸ” Sub-Question 1: How does CRISPR target tumor suppressor genes?   â”‚â”‚
â”‚ â”‚   â”‚  â”‚   Status: ğŸŸ¡ Partially Answered  â”‚  Evidence: 8 papers              â”‚â”‚
â”‚ â”‚   â”‚  â”‚                                                                     â”‚â”‚
â”‚ â”‚   â”‚  â”œâ”€ ğŸ“„ Evidence: PMID:12345678 - "CRISPR targeting of TP53..."       â”‚â”‚
â”‚ â”‚   â”‚  â”‚   âœ… Supports  â”‚  Relevance: 9/10  â”‚  Key: "Demonstrates..."      â”‚â”‚
â”‚ â”‚   â”‚  â”‚                                                                     â”‚â”‚
â”‚ â”‚   â”‚  â”œâ”€ ğŸ“„ Evidence: PMID:23456789 - "Cas9 specificity in..."            â”‚â”‚
â”‚ â”‚   â”‚  â”‚   âœ… Supports  â”‚  Relevance: 7/10                                  â”‚â”‚
â”‚ â”‚   â”‚  â”‚                                                                     â”‚â”‚
â”‚ â”‚   â”‚  â””â”€ ğŸ’¡ Hypothesis 1.1: "TP53 editing increases apoptosis"            â”‚â”‚
â”‚ â”‚   â”‚      Status: ğŸ§ª Testing  â”‚  Confidence: Medium                        â”‚â”‚
â”‚ â”‚   â”‚      Supporting: 5 papers  â”‚  Contradicting: 1 paper                 â”‚â”‚
â”‚ â”‚   â”‚      [View Details] [Link Experiment]                                 â”‚â”‚
â”‚ â”‚   â”‚                                                                        â”‚â”‚
â”‚ â”‚   â”œâ”€â–¶ ğŸ” Sub-Question 2: What are the off-target effects?                â”‚â”‚
â”‚ â”‚   â”‚     Status: ğŸ”´ Exploring  â”‚  Evidence: 6 papers                       â”‚â”‚
â”‚ â”‚   â”‚     [Expand]                                                          â”‚â”‚
â”‚ â”‚   â”‚                                                                        â”‚â”‚
â”‚ â”‚   â””â”€â–¶ ğŸ” Sub-Question 3: How to optimize delivery methods?               â”‚â”‚
â”‚ â”‚       Status: ğŸ”´ Exploring  â”‚  Evidence: 9 papers                         â”‚â”‚
â”‚ â”‚       [Expand]                                                            â”‚â”‚
â”‚ â”‚                                                                            â”‚â”‚
â”‚ â”‚ [+ Add Sub-Question]                                                       â”‚â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜â”‚
â”‚                                                                                 â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”â”‚
â”‚ â”‚ ğŸ’¡ Hypotheses Overview                                                      â”‚â”‚
â”‚ â”‚                                                                             â”‚â”‚
â”‚ â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”â”‚â”‚
â”‚ â”‚ â”‚ Hypothesis 1.1: TP53 editing increases apoptosis                       â”‚â”‚â”‚
â”‚ â”‚ â”‚ Linked to: Sub-Question 1  â”‚  Status: ğŸ§ª Testing  â”‚  Confidence: Med  â”‚â”‚â”‚
â”‚ â”‚ â”‚ Supporting: 5 papers  â”‚  Contradicting: 1 paper                        â”‚â”‚â”‚
â”‚ â”‚ â”‚ [View Evidence] [Link Experiment] [Update Status]                      â”‚â”‚â”‚
â”‚ â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜â”‚â”‚
â”‚ â”‚                                                                             â”‚â”‚
â”‚ â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”â”‚â”‚
â”‚ â”‚ â”‚ Hypothesis 2.1: Off-target effects correlate with guide RNA length     â”‚â”‚â”‚
â”‚ â”‚ â”‚ Linked to: Sub-Question 2  â”‚  Status: ğŸŸ¢ Supported  â”‚  Confidence: Hi â”‚â”‚â”‚
â”‚ â”‚ â”‚ Supporting: 8 papers  â”‚  Contradicting: 0 papers                       â”‚â”‚â”‚
â”‚ â”‚ â”‚ [View Evidence] [Mark as Confirmed]                                    â”‚â”‚â”‚
â”‚ â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜â”‚â”‚
â”‚ â”‚                                                                             â”‚â”‚
â”‚ â”‚ [+ Add Hypothesis]                                                          â”‚â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜â”‚
â”‚                                                                                 â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”â”‚
â”‚ â”‚ ğŸ“ˆ Progress Summary                                                         â”‚â”‚
â”‚ â”‚                                                                             â”‚â”‚
â”‚ â”‚ Questions: 1 main, 3 sub-questions                                          â”‚â”‚
â”‚ â”‚ Evidence: 23 papers linked to questions                                     â”‚â”‚
â”‚ â”‚ Hypotheses: 2 proposed, 1 testing, 1 supported                              â”‚â”‚
â”‚ â”‚ Experiments: 1 planned, 0 in progress                                       â”‚â”‚
â”‚ â”‚                                                                             â”‚â”‚
â”‚ â”‚ [Generate Living Summary] [Export Structure]                                â”‚â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### Key UI Components

**1. Question Card**
```typescript
interface QuestionCardProps {
  question: {
    question_id: string;
    question_text: string;
    question_type: 'main' | 'sub' | 'exploratory';
    status: 'exploring' | 'answered' | 'parked';
    priority: 'high' | 'medium' | 'low';
    evidence_count: number;
    hypothesis_count: number;
    depth_level: number;
  };
  onExpand: () => void;
  onAddSubQuestion: () => void;
  onLinkPapers: () => void;
}
```

**2. Evidence Link Component**
```typescript
interface EvidenceLinkProps {
  evidence: {
    article_pmid: string;
    article_title: string;
    evidence_type: 'supports' | 'contradicts' | 'context';
    relevance_score: number; // 1-10
    key_finding: string;
  };
  onViewPaper: () => void;
  onEditLink: () => void;
  onRemoveLink: () => void;
}
```

**3. Hypothesis Card**
```typescript
interface HypothesisCardProps {
  hypothesis: {
    hypothesis_id: string;
    hypothesis_text: string;
    question_id: string;
    status: 'proposed' | 'testing' | 'supported' | 'rejected';
    confidence_level: 'low' | 'medium' | 'high';
    supporting_evidence_count: number;
    contradicting_evidence_count: number;
  };
  onViewEvidence: () => void;
  onLinkExperiment: () => void;
  onUpdateStatus: () => void;
}
```

---

## ğŸ“¥ Part 2: Inbox Tab (NEW - Smart Triage)

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ“¥ Inbox - Smart Paper Triage                                                   â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                                 â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”â”‚
â”‚ â”‚ Filters: [ğŸ”´ Must Read (5)] [ğŸŸ¡ Nice to Know (12)] [âšª Ignore (3)]         â”‚â”‚
â”‚ â”‚          [ğŸ“… This Week] [ğŸ¯ By Question] [ğŸ”¬ By Impact]                    â”‚â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜â”‚
â”‚                                                                                 â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”â”‚
â”‚ â”‚ ğŸ”´ MUST READ                                                                â”‚â”‚
â”‚ â”‚                                                                             â”‚â”‚
â”‚ â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”â”‚â”‚
â”‚ â”‚ â”‚ ğŸ“„ CRISPR-Cas9 off-target effects in cancer cells                       â”‚â”‚â”‚
â”‚ â”‚ â”‚ Authors: Smith et al. â”‚ Nature 2024 â”‚ PMID: 38901234                   â”‚â”‚â”‚
â”‚ â”‚ â”‚                                                                         â”‚â”‚â”‚
â”‚ â”‚ â”‚ ğŸ¤– AI Assessment:                                                       â”‚â”‚â”‚
â”‚ â”‚ â”‚ Relevance: 95/100 â”‚ Impact: ğŸ”´ HIGH                                    â”‚â”‚â”‚
â”‚ â”‚ â”‚                                                                         â”‚â”‚â”‚
â”‚ â”‚ â”‚ ğŸ’¡ Why this matters:                                                    â”‚â”‚â”‚
â”‚ â”‚ â”‚ â€¢ Directly addresses Sub-Question 2 (off-target effects)               â”‚â”‚â”‚
â”‚ â”‚ â”‚ â€¢ Contradicts Hypothesis 2.1 (guide RNA length correlation)            â”‚â”‚â”‚
â”‚ â”‚ â”‚ â€¢ Introduces new mechanism not in your current model                   â”‚â”‚â”‚
â”‚ â”‚ â”‚                                                                         â”‚â”‚â”‚
â”‚ â”‚ â”‚ ğŸ¯ Affected:                                                            â”‚â”‚â”‚
â”‚ â”‚ â”‚ â€¢ Question 2: "What are the off-target effects?"                       â”‚â”‚â”‚
â”‚ â”‚ â”‚ â€¢ Hypothesis 2.1: May need revision                                    â”‚â”‚â”‚
â”‚ â”‚ â”‚                                                                         â”‚â”‚â”‚
â”‚ â”‚ â”‚ [ğŸ“– Read Now] [ğŸ”— Link to Question 2] [â­ï¸ Nice to Know] [âŒ Ignore]   â”‚â”‚â”‚
â”‚ â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜â”‚â”‚
â”‚ â”‚                                                                             â”‚â”‚
â”‚ â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”â”‚â”‚
â”‚ â”‚ â”‚ ğŸ“„ Optimizing CRISPR delivery via nanoparticles                         â”‚â”‚â”‚
â”‚ â”‚ â”‚ Authors: Johnson et al. â”‚ Cell 2024 â”‚ PMID: 38901235                   â”‚â”‚â”‚
â”‚ â”‚ â”‚                                                                         â”‚â”‚â”‚
â”‚ â”‚ â”‚ ğŸ¤– AI Assessment:                                                       â”‚â”‚â”‚
â”‚ â”‚ â”‚ Relevance: 88/100 â”‚ Impact: ğŸŸ¡ MEDIUM                                  â”‚â”‚â”‚
â”‚ â”‚ â”‚                                                                         â”‚â”‚â”‚
â”‚ â”‚ â”‚ ğŸ’¡ Why this matters:                                                    â”‚â”‚â”‚
â”‚ â”‚ â”‚ â€¢ Provides methodology for Sub-Question 3 (delivery optimization)      â”‚â”‚â”‚
â”‚ â”‚ â”‚ â€¢ Could inform future experiments                                      â”‚â”‚â”‚
â”‚ â”‚ â”‚                                                                         â”‚â”‚â”‚
â”‚ â”‚ â”‚ [ğŸ“– Read Now] [ğŸ”— Link to Question 3] [â­ï¸ Nice to Know] [âŒ Ignore]   â”‚â”‚â”‚
â”‚ â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜â”‚â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜â”‚
â”‚                                                                                 â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”â”‚
â”‚ â”‚ ğŸŸ¡ NICE TO KNOW (Collapsed)                                                 â”‚â”‚
â”‚ â”‚ 12 papers - Background context and related work                             â”‚â”‚
â”‚ â”‚ [Expand]                                                                    â”‚â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### Triage Actions

**Quick Actions:**
- ğŸ“– Read Now â†’ Opens PDF viewer + Creates "reading" status
- ğŸ”— Link to Question â†’ Opens modal to select question + evidence type
- â­ï¸ Nice to Know â†’ Moves to "nice to know" category
- âŒ Ignore â†’ Removes from inbox

**Bulk Actions:**
- Select multiple papers
- Bulk link to question
- Bulk mark as read
- Bulk ignore

---

## ğŸ“ Part 3: Decisions Tab (NEW - Decision Timeline)

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ“ Decisions & Pivots                                                           â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                                 â”‚
â”‚ [+ Log Decision] [ğŸ“… Timeline View] [ğŸ“Š By Type] [ğŸ” Search]                   â”‚
â”‚                                                                                 â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”â”‚
â”‚ â”‚ ğŸ“… Timeline View                                                            â”‚â”‚
â”‚ â”‚                                                                             â”‚â”‚
â”‚ â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”â”‚â”‚
â”‚ â”‚ â”‚ ğŸ”„ PIVOT - November 15, 2024                                            â”‚â”‚â”‚
â”‚ â”‚ â”‚ Decided by: Dr. Sarah Chen                                              â”‚â”‚â”‚
â”‚ â”‚ â”‚                                                                         â”‚â”‚â”‚
â”‚ â”‚ â”‚ Decision: Shift focus from TP53 to KRAS targeting                      â”‚â”‚â”‚
â”‚ â”‚ â”‚                                                                         â”‚â”‚â”‚
â”‚ â”‚ â”‚ ğŸ“‹ Rationale:                                                           â”‚â”‚â”‚
â”‚ â”‚ â”‚ Recent papers (PMID: 38901234, 38901235) show KRAS mutations are      â”‚â”‚â”‚
â”‚ â”‚ â”‚ more prevalent in our target cancer type (pancreatic). TP53 pathway   â”‚â”‚â”‚
â”‚ â”‚ â”‚ shows high off-target effects.                                         â”‚â”‚â”‚
â”‚ â”‚ â”‚                                                                         â”‚â”‚â”‚
â”‚ â”‚ â”‚ ğŸ”€ Alternatives Considered:                                             â”‚â”‚â”‚
â”‚ â”‚ â”‚ 1. Continue with TP53 (rejected: high off-target risk)                â”‚â”‚â”‚
â”‚ â”‚ â”‚ 2. Dual targeting TP53 + KRAS (rejected: too complex for PhD scope)   â”‚â”‚â”‚
â”‚ â”‚ â”‚ 3. Focus on KRAS only (selected)                                       â”‚â”‚â”‚
â”‚ â”‚ â”‚                                                                         â”‚â”‚â”‚
â”‚ â”‚ â”‚ ğŸ“Š Impact Assessment:                                                   â”‚â”‚â”‚
â”‚ â”‚ â”‚ â€¢ Affected Questions: Sub-Question 1 (now focuses on KRAS)            â”‚â”‚â”‚
â”‚ â”‚ â”‚ â€¢ Affected Hypotheses: Hypothesis 1.1 (archived), new H1.2 created    â”‚â”‚â”‚
â”‚ â”‚ â”‚ â€¢ Papers to re-evaluate: 8 papers now less relevant                   â”‚â”‚â”‚
â”‚ â”‚ â”‚ â€¢ New literature search needed: KRAS + CRISPR                          â”‚â”‚â”‚
â”‚ â”‚ â”‚                                                                         â”‚â”‚â”‚
â”‚ â”‚ â”‚ ğŸ“ Related Papers: 2 papers                                            â”‚â”‚â”‚
â”‚ â”‚ â”‚ [View Full Decision] [Edit] [Link More Papers]                         â”‚â”‚â”‚
â”‚ â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜â”‚â”‚
â”‚ â”‚                                                                             â”‚â”‚
â”‚ â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”â”‚â”‚
â”‚ â”‚ â”‚ ğŸ”¬ METHODOLOGY - October 20, 2024                                       â”‚â”‚â”‚
â”‚ â”‚ â”‚ Decided by: Dr. Sarah Chen                                              â”‚â”‚â”‚
â”‚ â”‚ â”‚                                                                         â”‚â”‚â”‚
â”‚ â”‚ â”‚ Decision: Use lentiviral delivery instead of electroporation           â”‚â”‚â”‚
â”‚ â”‚ â”‚                                                                         â”‚â”‚â”‚
â”‚ â”‚ â”‚ ğŸ“‹ Rationale:                                                           â”‚â”‚â”‚
â”‚ â”‚ â”‚ Literature review shows lentiviral has 3x higher efficiency in our     â”‚â”‚â”‚
â”‚ â”‚ â”‚ cell type. Electroporation causes too much cell death.                 â”‚â”‚â”‚
â”‚ â”‚ â”‚                                                                         â”‚â”‚â”‚
â”‚ â”‚ â”‚ [View Full Decision]                                                    â”‚â”‚â”‚
â”‚ â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜â”‚â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### Decision Form Modal

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ“ Log a Decision                                          [âœ•]  â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                 â”‚
â”‚ Decision Type:                                                  â”‚
â”‚ â—‹ Pivot  â—‹ Methodology  â—‹ Scope  â—‹ Hypothesis  â—‹ Other        â”‚
â”‚                                                                 â”‚
â”‚ Title:                                                          â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”â”‚
â”‚ â”‚ Shift focus from TP53 to KRAS targeting                    â”‚â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜â”‚
â”‚                                                                 â”‚
â”‚ Description:                                                    â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”â”‚
â”‚ â”‚ After reviewing recent literature, we're pivoting to...    â”‚â”‚
â”‚ â”‚                                                             â”‚â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜â”‚
â”‚                                                                 â”‚
â”‚ Rationale:                                                      â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”â”‚
â”‚ â”‚ KRAS mutations more prevalent in target cancer type...     â”‚â”‚
â”‚ â”‚                                                             â”‚â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜â”‚
â”‚                                                                 â”‚
â”‚ Alternatives Considered:                                        â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”â”‚
â”‚ â”‚ 1. Continue with TP53 - rejected due to...                 â”‚â”‚
â”‚ â”‚ 2. Dual targeting - rejected due to...                     â”‚â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜â”‚
â”‚                                                                 â”‚
â”‚ Impact Assessment:                                              â”‚
â”‚ Affected Questions: [Select Questions â–¼]                       â”‚
â”‚ â˜‘ Sub-Question 1: How does CRISPR target tumor suppressor...  â”‚
â”‚                                                                 â”‚
â”‚ Affected Hypotheses: [Select Hypotheses â–¼]                     â”‚
â”‚ â˜‘ Hypothesis 1.1: TP53 editing increases apoptosis            â”‚
â”‚                                                                 â”‚
â”‚ Related Papers: [Link Papers]                                  â”‚
â”‚ â€¢ PMID: 38901234 - "KRAS mutations in pancreatic cancer"      â”‚
â”‚ â€¢ PMID: 38901235 - "TP53 off-target effects"                  â”‚
â”‚                                                                 â”‚
â”‚                    [Cancel]  [Save Decision]                   â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

## ğŸ§ª Part 4: Experiments Tab (NEW - Lab Bridge)

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ§ª Experiments & Protocols                                                      â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                                 â”‚
â”‚ [+ Plan Experiment] [ğŸ“‹ View Protocols] [ğŸ“Š By Status] [ğŸ”— By Hypothesis]      â”‚
â”‚                                                                                 â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”â”‚
â”‚ â”‚ ğŸ“Š Experiments Overview                                                     â”‚â”‚
â”‚ â”‚                                                                             â”‚â”‚
â”‚ â”‚ Status: [ğŸ”µ Planned: 2] [ğŸŸ¡ In Progress: 1] [ğŸŸ¢ Completed: 0] [ğŸ”´ Failed: 0]â”‚â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜â”‚
â”‚                                                                                 â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”â”‚
â”‚ â”‚ ğŸ”µ PLANNED                                                                  â”‚â”‚
â”‚ â”‚                                                                             â”‚â”‚
â”‚ â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”â”‚â”‚
â”‚ â”‚ â”‚ Experiment 1: KRAS G12C targeting with Cas9                             â”‚â”‚â”‚
â”‚ â”‚ â”‚ Status: ğŸ”µ Planned â”‚ Start: Dec 1, 2024                                 â”‚â”‚â”‚
â”‚ â”‚ â”‚                                                                         â”‚â”‚â”‚
â”‚ â”‚ â”‚ ğŸ¯ Tests Hypothesis:                                                    â”‚â”‚â”‚
â”‚ â”‚ â”‚ Hypothesis 1.2: "KRAS G12C editing reduces cell proliferation"         â”‚â”‚â”‚
â”‚ â”‚ â”‚                                                                         â”‚â”‚â”‚
â”‚ â”‚ â”‚ ğŸ“‹ Protocol: Lentiviral CRISPR delivery (from PMID: 38901236)          â”‚â”‚â”‚
â”‚ â”‚ â”‚ [View Protocol Details]                                                 â”‚â”‚â”‚
â”‚ â”‚ â”‚                                                                         â”‚â”‚â”‚
â”‚ â”‚ â”‚ ğŸ“ Objective:                                                           â”‚â”‚â”‚
â”‚ â”‚ â”‚ Test whether CRISPR-mediated knockout of KRAS G12C mutation reduces    â”‚â”‚â”‚
â”‚ â”‚ â”‚ proliferation in pancreatic cancer cell line PANC-1.                   â”‚â”‚â”‚
â”‚ â”‚ â”‚                                                                         â”‚â”‚â”‚
â”‚ â”‚ â”‚ ğŸ“ Related Papers: 3 papers                                            â”‚â”‚â”‚
â”‚ â”‚ â”‚ â€¢ PMID: 38901236 - Protocol source                                     â”‚â”‚â”‚
â”‚ â”‚ â”‚ â€¢ PMID: 38901237 - Background on KRAS G12C                             â”‚â”‚â”‚
â”‚ â”‚ â”‚ â€¢ PMID: 38901238 - Expected outcomes                                   â”‚â”‚â”‚
â”‚ â”‚ â”‚                                                                         â”‚â”‚â”‚
â”‚ â”‚ â”‚ [â–¶ï¸ Start Experiment] [âœï¸ Edit Plan] [ğŸ“‹ View Protocol] [ğŸ—‘ï¸ Delete]   â”‚â”‚â”‚
â”‚ â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜â”‚â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜â”‚
â”‚                                                                                 â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”â”‚
â”‚ â”‚ ğŸŸ¡ IN PROGRESS                                                              â”‚â”‚
â”‚ â”‚                                                                             â”‚â”‚
â”‚ â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”â”‚â”‚
â”‚ â”‚ â”‚ Experiment 2: Off-target analysis with guide RNA variants               â”‚â”‚â”‚
â”‚ â”‚ â”‚ Status: ğŸŸ¡ In Progress â”‚ Started: Nov 10, 2024 â”‚ Day 7 of 14           â”‚â”‚â”‚
â”‚ â”‚ â”‚                                                                         â”‚â”‚â”‚
â”‚ â”‚ â”‚ ğŸ¯ Tests Hypothesis:                                                    â”‚â”‚â”‚
â”‚ â”‚ â”‚ Hypothesis 2.1: "Off-target effects correlate with guide RNA length"   â”‚â”‚â”‚
â”‚ â”‚ â”‚                                                                         â”‚â”‚â”‚
â”‚ â”‚ â”‚ ğŸ“‹ Protocol: Off-target detection assay (from PMID: 38901239)          â”‚â”‚â”‚
â”‚ â”‚ â”‚                                                                         â”‚â”‚â”‚
â”‚ â”‚ â”‚ ğŸ“Š Progress Notes:                                                      â”‚â”‚â”‚
â”‚ â”‚ â”‚ â€¢ Day 1-3: Cell culture and transfection âœ…                            â”‚â”‚â”‚
â”‚ â”‚ â”‚ â€¢ Day 4-7: Incubation and monitoring âœ…                                â”‚â”‚â”‚
â”‚ â”‚ â”‚ â€¢ Day 8-10: DNA extraction (upcoming)                                  â”‚â”‚â”‚
â”‚ â”‚ â”‚ â€¢ Day 11-14: Sequencing and analysis (upcoming)                        â”‚â”‚â”‚
â”‚ â”‚ â”‚                                                                         â”‚â”‚â”‚
â”‚ â”‚ â”‚ [ğŸ“ Add Note] [âœ… Mark Complete] [âŒ Mark Failed] [ğŸ“‹ View Protocol]   â”‚â”‚â”‚
â”‚ â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜â”‚â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜â”‚
â”‚                                                                                 â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”â”‚
â”‚ â”‚ ğŸ“‹ Protocols Library (5 protocols extracted)                                â”‚â”‚
â”‚ â”‚                                                                             â”‚â”‚
â”‚ â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”â”‚â”‚
â”‚ â”‚ â”‚ ğŸ“‹ Lentiviral CRISPR delivery                                           â”‚â”‚â”‚
â”‚ â”‚ â”‚ Source: PMID: 38901236 â”‚ Type: Delivery â”‚ Difficulty: Moderate         â”‚â”‚â”‚
â”‚ â”‚ â”‚ Duration: 5-7 days                                                      â”‚â”‚â”‚
â”‚ â”‚ â”‚                                                                         â”‚â”‚â”‚
â”‚ â”‚ â”‚ ğŸ”¬ Materials:                                                           â”‚â”‚â”‚
â”‚ â”‚ â”‚ â€¢ Lentiviral packaging plasmids (psPAX2, pMD2.G)                       â”‚â”‚â”‚
â”‚ â”‚ â”‚ â€¢ HEK293T cells for virus production                                   â”‚â”‚â”‚
â”‚ â”‚ â”‚ â€¢ Polybrene (8 Î¼g/mL)                                                  â”‚â”‚â”‚
â”‚ â”‚ â”‚                                                                         â”‚â”‚â”‚
â”‚ â”‚ â”‚ ğŸ“ Steps: 8 steps                                                       â”‚â”‚â”‚
â”‚ â”‚ â”‚ [View Full Protocol] [Use in Experiment] [Export]                      â”‚â”‚â”‚
â”‚ â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜â”‚â”‚
â”‚ â”‚                                                                             â”‚â”‚
â”‚ â”‚ [View All Protocols]                                                        â”‚â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### Protocol Detail View

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ“‹ Protocol: Lentiviral CRISPR Delivery                   [âœ•]  â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                 â”‚
â”‚ Source: PMID: 38901236 - "Optimized lentiviral delivery..."   â”‚
â”‚ [View Source Paper]                                             â”‚
â”‚                                                                 â”‚
â”‚ Type: Delivery â”‚ Difficulty: Moderate â”‚ Duration: 5-7 days     â”‚
â”‚                                                                 â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”â”‚
â”‚ â”‚ ğŸ”¬ Materials                                                â”‚â”‚
â”‚ â”‚                                                             â”‚â”‚
â”‚ â”‚ Plasmids:                                                   â”‚â”‚
â”‚ â”‚ â€¢ psPAX2 (packaging) - Addgene #12260                      â”‚â”‚
â”‚ â”‚ â€¢ pMD2.G (envelope) - Addgene #12259                       â”‚â”‚
â”‚ â”‚ â€¢ pLentiCRISPR v2 (transfer) - Addgene #52961              â”‚â”‚
â”‚ â”‚                                                             â”‚â”‚
â”‚ â”‚ Cells:                                                      â”‚â”‚
â”‚ â”‚ â€¢ HEK293T (virus production) - ATCC CRL-3216               â”‚â”‚
â”‚ â”‚ â€¢ Target cells (your experimental cells)                   â”‚â”‚
â”‚ â”‚                                                             â”‚â”‚
â”‚ â”‚ Reagents:                                                   â”‚â”‚
â”‚ â”‚ â€¢ Polybrene (8 Î¼g/mL) - Sigma TR-1003                      â”‚â”‚
â”‚ â”‚ â€¢ DMEM + 10% FBS                                           â”‚â”‚
â”‚ â”‚ â€¢ Opti-MEM (for transfection)                              â”‚â”‚
â”‚ â”‚ â€¢ Lipofectamine 3000                                       â”‚â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜â”‚
â”‚                                                                 â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”â”‚
â”‚ â”‚ ğŸ“ Procedure (8 steps)                                      â”‚â”‚
â”‚ â”‚                                                             â”‚â”‚
â”‚ â”‚ Day 1: Seed HEK293T cells                                  â”‚â”‚
â”‚ â”‚ â€¢ Seed 4Ã—10â¶ cells per 10cm dish                           â”‚â”‚
â”‚ â”‚ â€¢ Incubate overnight at 37Â°C, 5% COâ‚‚                       â”‚â”‚
â”‚ â”‚ â€¢ Target: 70-80% confluency next day                       â”‚â”‚
â”‚ â”‚                                                             â”‚â”‚
â”‚ â”‚ Day 2: Transfection                                        â”‚â”‚
â”‚ â”‚ â€¢ Mix plasmids: 10Î¼g transfer + 7.5Î¼g psPAX2 + 2.5Î¼g pMD2.Gâ”‚â”‚
â”‚ â”‚ â€¢ Add Lipofectamine 3000 per manufacturer protocol         â”‚â”‚
â”‚ â”‚ â€¢ Incubate 6 hours, then replace with fresh media          â”‚â”‚
â”‚ â”‚                                                             â”‚â”‚
â”‚ â”‚ Day 3: First harvest                                       â”‚â”‚
â”‚ â”‚ â€¢ Collect supernatant at 48h post-transfection             â”‚â”‚
â”‚ â”‚ â€¢ Filter through 0.45Î¼m filter                             â”‚â”‚
â”‚ â”‚ â€¢ Store at 4Â°C or use immediately                          â”‚â”‚
â”‚ â”‚                                                             â”‚â”‚
â”‚ â”‚ [... 5 more steps ...]                                     â”‚â”‚
â”‚ â”‚                                                             â”‚â”‚
â”‚ â”‚ [Expand All Steps]                                          â”‚â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜â”‚
â”‚                                                                 â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”â”‚
â”‚ â”‚ âš ï¸ Critical Notes                                           â”‚â”‚
â”‚ â”‚                                                             â”‚â”‚
â”‚ â”‚ â€¢ Use fresh Lipofectamine for best results                 â”‚â”‚
â”‚ â”‚ â€¢ Do not exceed 80% confluency for transfection            â”‚â”‚
â”‚ â”‚ â€¢ Virus titer decreases after 72h - harvest promptly       â”‚â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜â”‚
â”‚                                                                 â”‚
â”‚ [Use in Experiment] [Export to ELN] [Edit Protocol] [Close]   â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

## ğŸ“Š Part 5: Living Summary Tab (NEW - Auto-Updated Review)

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ“Š Living Literature Summary                                                    â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                                 â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”â”‚
â”‚ â”‚ Summary Status                                                              â”‚â”‚
â”‚ â”‚                                                                             â”‚â”‚
â”‚ â”‚ Last Updated: Nov 15, 2024 â”‚ Version: 3 â”‚ Papers: 23 â”‚ Sections: 4         â”‚â”‚
â”‚ â”‚                                                                             â”‚â”‚
â”‚ â”‚ ğŸ”„ 5 new papers since last update                                           â”‚â”‚
â”‚ â”‚ [ğŸ”„ Update Summary with New Papers] [ğŸ“¥ Export to Word] [ğŸ“‹ View History]  â”‚â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜â”‚
â”‚                                                                                 â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”â”‚
â”‚ â”‚ ğŸ“– Summary Content (Organized by Research Questions)                        â”‚â”‚
â”‚ â”‚                                                                             â”‚â”‚
â”‚ â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”â”‚â”‚
â”‚ â”‚ â”‚ 1. CRISPR Mechanisms in Cancer Therapy (Main Question)                  â”‚â”‚â”‚
â”‚ â”‚ â”‚                                                                         â”‚â”‚â”‚
â”‚ â”‚ â”‚ CRISPR-Cas9 has emerged as a promising tool for cancer therapy by      â”‚â”‚â”‚
â”‚ â”‚ â”‚ enabling precise genomic modifications. Current research focuses on     â”‚â”‚â”‚
â”‚ â”‚ â”‚ three main areas: tumor suppressor gene targeting, off-target effect   â”‚â”‚â”‚
â”‚ â”‚ â”‚ mitigation, and delivery optimization.                                  â”‚â”‚â”‚
â”‚ â”‚ â”‚                                                                         â”‚â”‚â”‚
â”‚ â”‚ â”‚ Evidence: 23 papers                                                     â”‚â”‚â”‚
â”‚ â”‚ â”‚ Key Papers: PMID:38901234, PMID:38901235, PMID:38901236               â”‚â”‚â”‚
â”‚ â”‚ â”‚                                                                         â”‚â”‚â”‚
â”‚ â”‚ â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â” â”‚â”‚â”‚
â”‚ â”‚ â”‚ â”‚ 1.1 Tumor Suppressor Gene Targeting (Sub-Question 1)             â”‚ â”‚â”‚â”‚
â”‚ â”‚ â”‚ â”‚                                                                   â”‚ â”‚â”‚â”‚
â”‚ â”‚ â”‚ â”‚ Recent studies have shifted focus from TP53 to KRAS targeting    â”‚ â”‚â”‚â”‚
â”‚ â”‚ â”‚ â”‚ due to higher prevalence in certain cancer types. KRAS G12C      â”‚ â”‚â”‚â”‚
â”‚ â”‚ â”‚ â”‚ mutation is particularly targetable with current CRISPR systems. â”‚ â”‚â”‚â”‚
â”‚ â”‚ â”‚ â”‚                                                                   â”‚ â”‚â”‚â”‚
â”‚ â”‚ â”‚ â”‚ Key Findings:                                                     â”‚ â”‚â”‚â”‚
â”‚ â”‚ â”‚ â”‚ â€¢ KRAS mutations present in 90% of pancreatic cancers [1,2]     â”‚ â”‚â”‚â”‚
â”‚ â”‚ â”‚ â”‚ â€¢ G12C variant is most amenable to CRISPR editing [3]           â”‚ â”‚â”‚â”‚
â”‚ â”‚ â”‚ â”‚ â€¢ TP53 targeting shows high off-target effects [4]              â”‚ â”‚â”‚â”‚
â”‚ â”‚ â”‚ â”‚                                                                   â”‚ â”‚â”‚â”‚
â”‚ â”‚ â”‚ â”‚ Evidence: 8 papers                                                â”‚ â”‚â”‚â”‚
â”‚ â”‚ â”‚ â”‚ [View All Papers] [Add to This Section]                          â”‚ â”‚â”‚â”‚
â”‚ â”‚ â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜ â”‚â”‚â”‚
â”‚ â”‚ â”‚                                                                         â”‚â”‚â”‚
â”‚ â”‚ â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â” â”‚â”‚â”‚
â”‚ â”‚ â”‚ â”‚ 1.2 Off-Target Effects (Sub-Question 2)                          â”‚ â”‚â”‚â”‚
â”‚ â”‚ â”‚ â”‚                                                                   â”‚ â”‚â”‚â”‚
â”‚ â”‚ â”‚ â”‚ Off-target effects remain a major concern for clinical           â”‚ â”‚â”‚â”‚
â”‚ â”‚ â”‚ â”‚ translation. Recent work has identified guide RNA length and     â”‚ â”‚â”‚â”‚
â”‚ â”‚ â”‚ â”‚ sequence composition as key determinants.                        â”‚ â”‚â”‚â”‚
â”‚ â”‚ â”‚ â”‚                                                                   â”‚ â”‚â”‚â”‚
â”‚ â”‚ â”‚ â”‚ Key Findings:                                                     â”‚ â”‚â”‚â”‚
â”‚ â”‚ â”‚ â”‚ â€¢ 20-mer guides show fewer off-targets than 17-mer [5]          â”‚ â”‚â”‚â”‚
â”‚ â”‚ â”‚ â”‚ â€¢ GC content >60% increases specificity [6]                     â”‚ â”‚â”‚â”‚
â”‚ â”‚ â”‚ â”‚ â€¢ High-fidelity Cas9 variants reduce off-targets by 10x [7]     â”‚ â”‚â”‚â”‚
â”‚ â”‚ â”‚ â”‚                                                                   â”‚ â”‚â”‚â”‚
â”‚ â”‚ â”‚ â”‚ âš ï¸ Recent Update (Nov 15):                                       â”‚ â”‚â”‚â”‚
â”‚ â”‚ â”‚ â”‚ New paper (PMID:38901234) contradicts guide RNA length          â”‚ â”‚â”‚â”‚
â”‚ â”‚ â”‚ â”‚ hypothesis - suggests sequence context matters more.             â”‚ â”‚â”‚â”‚
â”‚ â”‚ â”‚ â”‚                                                                   â”‚ â”‚â”‚â”‚
â”‚ â”‚ â”‚ â”‚ Evidence: 6 papers                                                â”‚ â”‚â”‚â”‚
â”‚ â”‚ â”‚ â”‚ [View All Papers] [Add to This Section]                          â”‚ â”‚â”‚â”‚
â”‚ â”‚ â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜ â”‚â”‚â”‚
â”‚ â”‚ â”‚                                                                         â”‚â”‚â”‚
â”‚ â”‚ â”‚ [Expand All Sections]                                                   â”‚â”‚â”‚
â”‚ â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜â”‚â”‚
â”‚ â”‚                                                                             â”‚â”‚
â”‚ â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”â”‚â”‚
â”‚ â”‚ â”‚ ğŸ“Š Summary Statistics                                                   â”‚â”‚â”‚
â”‚ â”‚ â”‚                                                                         â”‚â”‚â”‚
â”‚ â”‚ â”‚ Total Papers: 23                                                        â”‚â”‚â”‚
â”‚ â”‚ â”‚ Sections: 4 (organized by research questions)                           â”‚â”‚â”‚
â”‚ â”‚ â”‚ Last Major Update: Nov 15, 2024 (added 5 papers)                       â”‚â”‚â”‚
â”‚ â”‚ â”‚ Version History: 3 versions                                             â”‚â”‚â”‚
â”‚ â”‚ â”‚                                                                         â”‚â”‚â”‚
â”‚ â”‚ â”‚ Coverage:                                                               â”‚â”‚â”‚
â”‚ â”‚ â”‚ â€¢ Main Question: 23 papers                                              â”‚â”‚â”‚
â”‚ â”‚ â”‚ â€¢ Sub-Question 1: 8 papers                                              â”‚â”‚â”‚
â”‚ â”‚ â”‚ â€¢ Sub-Question 2: 6 papers                                              â”‚â”‚â”‚
â”‚ â”‚ â”‚ â€¢ Sub-Question 3: 9 papers                                              â”‚â”‚â”‚
â”‚ â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜â”‚â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜â”‚
â”‚                                                                                 â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”â”‚
â”‚ â”‚ ğŸ”„ Update Options                                                           â”‚â”‚
â”‚ â”‚                                                                             â”‚â”‚
â”‚ â”‚ [ğŸ”„ Update with 5 New Papers] - AI will integrate new findings             â”‚â”‚
â”‚ â”‚ [âœï¸ Manual Edit] - Edit summary text directly                              â”‚â”‚
â”‚ â”‚ [ğŸ“¥ Export to Word] - Download as .docx for thesis chapter                 â”‚â”‚
â”‚ â”‚ [ğŸ“‹ View Version History] - See how summary evolved                         â”‚â”‚
â”‚ â”‚ [ğŸ”— Share with Supervisor] - Generate shareable link                        â”‚â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

## ğŸ”” Part 6: Alerts Panel (NEW - Proactive Notifications)

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ”” Project Alerts                                          [âœ•]  â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                 â”‚
â”‚ [ğŸ”´ Critical (1)] [ğŸŸ¡ Medium (3)] [ğŸŸ¢ Low (2)] [âœ… Dismissed]  â”‚
â”‚                                                                 â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”â”‚
â”‚ â”‚ ğŸ”´ CRITICAL - Contradicting Evidence Found                 â”‚â”‚
â”‚ â”‚ Nov 15, 2024                                                â”‚â”‚
â”‚ â”‚                                                             â”‚â”‚
â”‚ â”‚ New paper contradicts Hypothesis 2.1                        â”‚â”‚
â”‚ â”‚                                                             â”‚â”‚
â”‚ â”‚ ğŸ“„ Paper: "Off-target effects in CRISPR systems"           â”‚â”‚
â”‚ â”‚ PMID: 38901234                                              â”‚â”‚
â”‚ â”‚                                                             â”‚â”‚
â”‚ â”‚ ğŸ’¡ Impact:                                                  â”‚â”‚
â”‚ â”‚ â€¢ Contradicts: Hypothesis 2.1 (guide RNA length)           â”‚â”‚
â”‚ â”‚ â€¢ Affects: Sub-Question 2 (off-target effects)             â”‚â”‚
â”‚ â”‚ â€¢ Action: Consider revising hypothesis or designing        â”‚â”‚
â”‚ â”‚   experiment to test both mechanisms                       â”‚â”‚
â”‚ â”‚                                                             â”‚â”‚
â”‚ â”‚ [ğŸ“– Read Paper] [ğŸ”— Link to Hypothesis] [âœ… Dismiss]       â”‚â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜â”‚
â”‚                                                                 â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”â”‚
â”‚ â”‚ ğŸŸ¡ MEDIUM - Gap in Literature Identified                   â”‚â”‚
â”‚ â”‚ Nov 12, 2024                                                â”‚â”‚
â”‚ â”‚                                                             â”‚â”‚
â”‚ â”‚ No papers address delivery optimization for your cell type â”‚â”‚
â”‚ â”‚                                                             â”‚â”‚
â”‚ â”‚ ğŸ’¡ Suggestion:                                              â”‚â”‚
â”‚ â”‚ â€¢ Consider this as a novel contribution                    â”‚â”‚
â”‚ â”‚ â€¢ May need to develop custom protocol                      â”‚â”‚
â”‚ â”‚ â€¢ Affects: Sub-Question 3 (delivery methods)               â”‚â”‚
â”‚ â”‚                                                             â”‚â”‚
â”‚ â”‚ [ğŸ“ Log as Decision] [âœ… Dismiss]                          â”‚â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜â”‚
â”‚                                                                 â”‚
â”‚ â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”â”‚
â”‚ â”‚ ğŸŸ¡ MEDIUM - New Relevant Paper                             â”‚â”‚
â”‚ â”‚ Nov 10, 2024                                                â”‚â”‚
â”‚ â”‚                                                             â”‚â”‚
â”‚ â”‚ Highly relevant paper published in Nature                  â”‚â”‚
â”‚ â”‚                                                             â”‚â”‚
â”‚ â”‚ ğŸ“„ Paper: "KRAS G12C targeting in pancreatic cancer"       â”‚â”‚
â”‚ â”‚ PMID: 38901240                                              â”‚â”‚
â”‚ â”‚                                                             â”‚â”‚
â”‚ â”‚ ğŸ’¡ Relevance:                                               â”‚â”‚
â”‚ â”‚ â€¢ Directly addresses Sub-Question 1                        â”‚â”‚
â”‚ â”‚ â€¢ Provides protocol for your planned experiment            â”‚â”‚
â”‚ â”‚ â€¢ Cited by 15 papers already                               â”‚â”‚
â”‚ â”‚                                                             â”‚â”‚
â”‚ â”‚ [ğŸ“– Read Paper] [ğŸ“¥ Add to Inbox] [âœ… Dismiss]             â”‚â”‚
â”‚ â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

## ğŸ¨ Part 7: Updated Tab Navigation

### Before (6 tabs)
```
[ğŸ¯ Research Question] [ğŸ” Explore] [ğŸ“š Collections] [ğŸ“ Notes] [ğŸ“Š Analysis] [ğŸ“ˆ Progress]
```

### After (9 tabs - Reordered & Enhanced)

```
[ğŸ¯ Questions] [ğŸ“¥ Inbox] [ğŸ” Explore] [ğŸ“š Collections] [ğŸ“ Decisions] [ğŸ§ª Experiments] [ğŸ“Š Summary] [ğŸ’¬ Notes] [ğŸ“ˆ Progress]
```

**Tab Descriptions:**

1. **ğŸ¯ Questions** (was "Research Question")
   - Tree structure of questions
   - Hypothesis tracking
   - Evidence linking
   - **Primary workflow tab**

2. **ğŸ“¥ Inbox** (NEW)
   - Smart paper triage
   - AI-powered relevance scoring
   - Quick actions to link to questions
   - **Entry point for new papers**

3. **ğŸ” Explore** (unchanged)
   - Network visualization
   - Citation maps
   - Paper discovery
   - **Keep existing functionality**

4. **ğŸ“š Collections** (enhanced)
   - Now linked to questions
   - Purpose tagging (evidence, methodology, background)
   - **Enhanced with question context**

5. **ğŸ“ Decisions** (NEW)
   - Decision timeline
   - Pivot tracking
   - Impact assessment
   - **Critical for PhD/R&D memory**

6. **ğŸ§ª Experiments** (NEW)
   - Experiment planning
   - Protocol library
   - Hypothesis testing
   - **Lab bridge**

7. **ğŸ“Š Summary** (NEW)
   - Living literature review
   - Auto-updated with new papers
   - Organized by questions
   - **Export to thesis chapter**

8. **ğŸ’¬ Notes** (was "Notes & Ideas", enhanced)
   - Now linkable to questions/hypotheses
   - **Enhanced with structure**

9. **ğŸ“ˆ Progress** (enhanced)
   - Now tracks questions, hypotheses, experiments
   - **More comprehensive metrics**

---

**Next**: See TECHNICAL_ARCHITECTURE_EVOLUTION.md for implementation details

